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Background: Alpha-1 antitrypsin (AAT) deficiency is an autosomal-codominant disorder,
caused by mutations in the SERPINA1 gene on chromosome 14. Individuals affected by the
most common mutations, SZ and ZZ, have serum AAT concentrations of 25% and 15% of
normal levels, and present a higher risk of emphysema. Mutations causing total absence of
serum AAT (Null mutations) were suggested to be associated with very early onset
emphysema but their clinical phenotype is poorly known.
Hypothesis: Absence of AAT in Null mutations results in more severe emphysema as
compared to ZZ and SZ.
Methods: We genotyped all known Dutch subjects (n ¼ 12) with absent serum AAT, and
compared their lung function values (FEV1 and KCO) with those of individuals with ZZ and SZ
genotype, matched for age and smoking history.
Results: All subjects with absent serum AAT presented homozygous Null mutations. In
three subjects, a new mutation in exon 2 of the SERPINA1 gene was found. Subjects with
Null mutations showed significantly lower lung function values than SZ and ZZ individuals
(p ¼ 0.000 and 0.001 for FEV1 and KCO, respectively). In all groups, there was a positive
correlation between serum AATand lung function values (p ¼ 0.025 and 0.014 for FEV1 and
KCO, respectively).
Conclusions: Serum levels of AAT are correlated with the severity of pulmonary
phenotype. Subjects with Null mutations should be considered a subgroup at particularly
high risk of emphysema within AAT deficiency (AATD). Early detection of carriers of this
genotype would be important for preventive and therapeutic interventions.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
262082.
nl (L. Fregonese).
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Alpha-1 antitrypsin (AAT) is the most prevalent serine
protease inhibitor in serum; it is synthesized by hepatocytes
and belongs to the family of serpins (serine protease
inhibitors).1 Its main role is that of inhibiting neutrophil
elastase (NE), an enzyme that degrades several components
of the extra cellular matrix in the lungs. Insufficient
inhibition of NE in AAT deficiency (AATD) can cause severe,
early age onset pulmonary emphysema, resulting in high
incidence of lung transplantation and reduced life expec-
tancy.2
AATD is one of the most common autosomal-codominant
genetic disorders in the Caucasian population.1,3 To date,
about 100 genetic variants of AAT have been identified.
The normal AAT genotype is Pi MM, (94–96% of the white
population),4–6 characterized by protein serum levels of
150–350mg/100ml (20–48 mM). The S variant, originated
in the Iberian Peninsula, and the Z variant, arisen in the
Viking population, account for more than 95% of the
mutations in patients with severe AATD.7,8 Both variants
are missense mutations in the serpina1 gene (SERPINA1)
on chromosome 14q32.1.9–11 In contrast to the S, the Z
phenotype is characterized by polymerization of AAT,
which can result in liver cirrhosis. Individuals with SS, SZ,
and ZZ genotypes have serum AAT concentrations of
approximately 85%, 25%, and 15% of normal levels,
respectively.12 Homozygosis for S mutation has not been
associated with disease. A very limited number of studies
investigated the different risk of developing emphysema
between ZZ and SZ genotypes.13,14 Most studies concluded
that the SZ genotype is less important than the ZZ in the
development of emphysema and SZ patients develop
emphysema at an older age than ZZ patients.1 However, it
is not know whether the different risk is linked to the
different AAT serum levels between the two populations or
to other, unknown, factors.
Among the variants within the SERPINA1, several muta-
tions have been described leading to total absence of AAT
production (Null mutations). Although the number of these
mutations is large, they are rare within the population, thus
very little is known about their clinical phenotype. In 1988,
Cox and Levison showed that lung disease associated with
Null homozygosis (Null Mattawa: Q0mat) was more severe
than that associated with ZZ genotype.15 The very small
sample size of that study (three homozygous sisters)
prevents generalizability of the findings; however, this study
and other sparse clinical reports seem to point to a higher
risk and severity of emphysema in subjects with absence of
AAT in serum. If this would be the case, early detection of
the Null homozygous genotype should be promoted and
should lead to stronger educational intervention (e.g.
smoking avoidance) and to a possible use of the replacement
therapy as preventive treatment. Recently, Ferrarotti
et al.16 reported lower values of FEV1 in subjects with rare
variants of AATas compared to ZZ; however, in their study ZZ
and rare variants had similar AAT plasma levels and the lung
function results were confounded by smoking. Thus, the
authors could not discriminate between the importance of
genetic factors (type of mutation), protein serum levels,
and environmental factors (smoking) in determining the
severity of the disease.Aim of our study was to analyze whether homozygous Null
genotype is related to severity of emphysema in AATD and
whether protein serum levels are the major determinants of
severity. To this aim, we characterized the SERPINA1
mutations in the Dutch Null population, we compared lung
function of Null subjects with that of ZZ and SZ subjects
matched for age and smoking history, and correlated the
functional data with AAT serum levels.
Methods
Subjects
All subjects included in the study were recruited from the
Alpha-1 International Registry database (AIR, www.aatregistry.
org). AIR is the largest international database of individuals
with AATD, containing lung function data, clinical history,
and AATD phenotype of more than 2600 individuals with
severe deficiency from 21 different countries, collected
in the years 1997–2006. A review with a detailed descrip-
tion of the AIR database development and methodo-
logy has been recently published.17 The Dutch part of the
AIR database includes a total of 290 subjects, and one of the
largest Null populations ever detected, composed by 12
subjects from 7 families. All 12 Null subjects were included
in our analysis.
Study design
The study had a matched-paired design.18 For each Null
case, a subject with ZZ and a subject with SZ genotype were
selected from the AIR Registry, matched on the basis of age
(75 years) and smoking (77 pack-years). Due to the young
age of the Null subjects, only one-to-one matches with
complete lung function data were found within the ZZ and
SZ population. The study was approved by the Ethics
Committee of the Leiden University Medical Centre and
patients gave their written informed consent.
Lung function
Lung function tests to determine the severity of emphysema
were performed according to the European Respiratory
Society guidelines.19,20 All tests were performed after
nebulization of 5mg of salbutamol and 500mcg of ipratro-
pium bromide. Among the lung function measurements,
forced expiratory volume as percentage of predicted
(ppFEV1) and the coefficient of diffusion of carbon monoxide
as percentage of predicted (ppKCO) were included in the
analysis, since they are currently considered as the most
relevant for determining emphysema severity in AATD.21,22
Serum AAT levels
Serum AAT levels were measured using a completely
automated immunoassay, as previously described.23 The
lower limit of detection of the assay is 10 nM. As confirma-
tion of absence of an AAT band observed in the gel of iso-
electrophoresis of serum samples, all subjects with AAT
serum values lower than 1.5 mM were considered as having
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gram per liter.
Statistical analysis
The software package SPSS 11.5 (SPSS inc., Chicago, USA)
was used. Due to their young age, for two Null/Null subjects
it was not possible to find in the database matched ZZ and SZ
subjects with KCO data. Therefore, only 10 subjects per
group were included in the analysis of KCO. Data are
expressed as mean (S.D.) when normally distributed, as
median (range) otherwise. For normally distributed data,
differences within the means of the three groups were
analyzed by the analysis of variance (ANOVA) test. Differ-
ences between two groups at one time were established
using as post-hoc the Student’s t-test. When data were not
normally distributed, Kruskal–Wallis test was used for
comparisons within the three groups and Mann–Whitney
test was applied post-hoc to compare two groups at a time.
Correlations between lung function parameters and AAT
serum levels were tested using the non-parametric Spear-
man’s correlation coefficient. The results were considered
statistically significant for p-values below 5%.
Genotype and haplotype analysis
Genotype analysis
Genomic DNA was isolated from 10ml of peripheral blood
using standard procedures.24 Genotypic analysis was per-
formed in the Null/Null subjects by direct sequencing after
PCR amplification of the all exons (1a, 1b, 1c, and 2–5) of
SERPINA1.
Primer sequences (obtained from K. Morgan, Nottingham,
UK) and annealing temperatures used for PCR amplificationTable 1 Primer sequences and annealing temperatures used fo
Exon Forward primer Reverse primer
1a AAGGCTCCTTCCTGTCCAAG CGCTGCTCTACATCCAC
1b/c CCATCAAGAGGGTGTTTGTGT CGGATACCCACTCCACA
2 GTACTTGGCACAGGCTGGTT ATGCATTGCCAAGGAGA
3 GAGGGATGTGTGTCGTCAAG TAGCAGTGACCCAGGGA
4 TAGTGTGGGTGGAGGACACA CAGCCTGGGTCTTCATT
5 GTGACAGGGAGGGAGAGGAT CTGTTACCTGGAGCCCA
Table 2 Primer sequences and annealing temperatures use
SERPINA1.
Marker Forward primer Reverse primer
D14S1054 F-ACAGTCACGTGGGCCA GGACCTGGGCATTT
D14S299 H-GATCTCAATAAACATTGATACTGG CTGCATGAGCTAAA
D14S1142 F-TTGCAGGGAGTCAGGTGTATG GCATCACACAGAGA
D14S749 H-CCCCCTCCCTTCCTATCTGT TAAAAGTGGTTGGT
SERPINA1 located at 98.88 cM on chromosome 14 (Decode map).are shown in Table 1. PCR products were purified using the
Qiagen PCR purification kit (Qiagen Benelux, Venlo, the
Netherlands). Sequencing was performed using the ABI Prism
BigDye Terminator Cycle Sequencing Ready Reaction kit
(Applied Biosystems, Arrington, UK) and products were
analyzed on the ABI 3730 sequencer. Total RNA was
extracted from fresh blood using the RNA Insta-Pure
extraction kit (Eurogentec, Maastricht, the Netherlands).
RNA was obtained from control individuals without A1ATD
and one A1ATD subject to determine the expression of a
novel Null mutation in blood monocytes. RNA from controls
and a homozygous Null patient was sequenced after RT-PCR
amplification using the forward primer of exon 4 and the
reverse primer of exon 5 to determine the allelic expression.
Haplotype analysis
Polymorphic markers (D14S1054, D14S299, D14S1142, and
D14S749) flanking SERPINA1 were used to determine the
haplotype inheritance within a family with a compound
heterozygous Null mutation (family E). Table 2 shows the
primers sequences and conditions for PCR amplification. The
forward primers of D14S1054 and D14S1142 were labeled
with FAM fluorophores; the forward primers of D14S299 and
D14S749 were labeled with HEX. PCR fragments were
analyzed on ABI3700 sequencer.
Results
Subjects
Characteristics of Null subjects
The characteristics of Null subjects are presented in Table 3.
Genotypes of the Null subjects are presented in Table 4.
Seventy-five percent of the subjects were current orr PCR amplification of the coding exons (2–5) of SERPINA1.
Annealing (1C) Size (bp) Coding region (bp)
TCA 58 494 163
AC 61 676 210 bp(b)/104 bp(c)
GTT 60 862 650
TGT 61 521 271
TGT 60 397 148
CAT 62 494 268
d for PCR amplification of polymorphic markers flanking
Annealing (1C) Product size (bp) Location (cM)
ATTCTG 55 152–166 100.7
GCATACTG 55 294–318 99.40
CACGGAT 55 155–189 98.86
GGGAAA 55 158–182 97.65
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Table 3 Characteristics of the homozygous Null (Null/Null) subjects.
Family Member Age Sex Smoking Pack-
years
Reason
assessment
FEV1
(% predicted)
KCO
(% predicted)
A1AT (mM/g/l)
A S1 43 m Y 2.50 1 28 37 0.024/0.18
A S2 41 f N 0 2 31 61 0.180/1.35
A S3 38 m N 0 1 65 69 0.330/2.475
B S1 41 f Y 25 1 59 67 0.320/2.4
B S2 55 m Y 15.2 1 25 56 0.280/2.1
C S1 42 m Y 4.8 2 24 47 0.014/0.105
C S2 49 m N 0 1 53 44 0.017/0.128
D S1 27 f Y 3 1 34 53 n.d.
D S2 23 m Y 0.6 2 82 63 n.d.
E S1 37 m Y 7 1 37 41 0.025/0.187
F S1 50 f Y 10.5 1 40 35 0.27/2.025
G S1 42 m Y 14.3 1 28 52 0.310/2.325
Table 4 Genomic mutations in individuals with absent serum AAT.
Family Family member Nucleotide change Mutated exons Amino-acid changes Name mutation
A Mother A737T 3 K217X/Normal PiNull Bellingham
Father A737T 3 K217X/Normal
Sibling 1 (Null) A737T/A737T 3/3 K217X/K217Xy
Sibling 2 (Null) A737T/A737T 3/3 K217X/K217X
Sibling 3 (Null) A737T/A737T 3/3 K217X/K217X
Sibling 4 A737T 3 K217X/Normal
B Sibling 1 (Null) C1195T/C1195T 5/5 P369L/P369L PiM Heerlen
Sibling 2 (Null) C1195T/C1195T 5/5 P369L/P369L
Sibling 3 – – Normal/Normal
Sibling 4 – – Normal/Normal
C Sibling 1 (Null) C548G/C548G 2/2 Y160X/Y160X PiNull Bredevoort
Sibling 2 (Null) C548G/C548G 2/2 Y160X/Y160X
D Mother A737T 3 K217X/Normal PiNull Bellingham
Father A737T 3 K217X/Normal
Sibling 1 (Null) A737T/A737T 3/3 K217X/K217X
Sibling 2 (Null) A737T/A737T 3/3 K217X/K217X
E Mother C1195T 5 P369L/Normal PiNullBredevoort/PiMHerleen
Father C548G 2 Y160X/Normal
Sibling 1 (Null) C548G/C1195T 2/5 Y160X/P369L
Sibling 2 C548G 2 Y160X/Normal
Sibling 3 C1195T 5 P369L/Normal
F Sibling 1 (Null) C1195T/C1195T 5/5 P369L/P369L PiM Heerlen
G Sibling 1 (Null) C1195T/C1195T 5/5 P369L/P369L PiM Heerlen
Nucleotides are numbered from the translation start site in exon 2.
yAmino-acids are numbered from the signal peptide cleavage site (the first methionine of A1AT is located at position 24).
Alpha-1 antitrypsin Null mutations and severity of emphysema 879ex-smokers. The reason of assessment was lung disease in 9
out of 12 subjects (75%), while the other 3 (25%) were
ascertained because of family screening. Similar results for
ascertainment were found in the SZ subjects (75% lung
disease vs. 25% family screening) while in the ZZ group
reason for ascertainment was lung disease in 10 subjects
(83%) and family screening in 2 (17%). In the Null population,lung function could vary between siblings from the same
family, even when the subjects had comparable age and
smoking history. In family A, sibling 2 (S2) and sibling 3 (S3)
had similar age and were both non-smokers, nevertheless S3
had almost double ppFEV1 than S2. Interestingly, these two
subjects had similar KCO impairment. Similarly, FEV1 was
different between S1 and S2 in family D, with much higher
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L. Fregonese et al.880FEV1 in S2. Discordant impairment of ppFEV1 and ppKCO was
noted in individuals A-S2, B-S2, and G-S1.
Genotype of Null subjects
Genomic mutations of SERPINA1 on chromosome 14 were
characterized in all 12 subjects with absent serum AAT.
All subjects were shown to be homozygous for Null
mutations (Null/Null). Whenever possible, genotypic analy-
sis was performed also in the first’s degree relatives of the
Null/Null subjects. The results are shown in Table 2. In five
families (A, B, D, F, and G), previously published mutations
were identified (PiNull Bellingham and PiM Heerlen).
Interestingly, a new mutation was found in three individuals
from two different families (C and E). A nucleotide
substitution of a C to G in exon 2 at position 548 (counted
from the translation start site of SERPINA1) resulted in a
premature stop codon (Y160X). Both siblings of family C
were homozygous carriers of the novel Null mutation, while
the subject in family E was shown to be a heterozygous
carrier. Haplotype analysis of family E is shown in Figure 1.
One of the haplotypes (gray) of the proband with the
Null/Null genotype (sibling 1: S1) is shared by his father (F)
and brother; the other haplotype (white) is shared by his
mother and sister. Sequence analysis showed that the white
haplotype is associated with the PiM Heerlen mutation in
exon V of SERPINA1 and the gray haplotype is associated
with the novel Null mutation in exon 2. The novel mutationFigure 1 Segregation in family E of four polymorphic markers
flanking SERPINA1, and of four intragenic single nucleotide
polymorphisms. The G in exon 2 of SERPINA1 causes the novel
PiNull Bredevoort mutation (gray haplotype); the T in exon 5
causes the PiM Heerlen mutation (white haplotype).is named PiNull Bredevoort after the place of residence of
the oldest known carrier (F).
We analyzed the expression of both alleles of the proband
S1 (containing the PiM Heerlen and the PiNull Bredevoort
mutation) in blood monocytes. Part of the DNA and cDNA
(RNA) sequences of exon 5 of SERPINA1 for the proband and
for a control are shown in Figure 2. The proband is
heterozygous for the T nucleotide of the PiM Heerlen
mutation, showing both alleles at DNA level (Figure 2a). At
cDNA level only the T nucleotide of the PiM Heerlen
mutation is observed, while the C-allele associated with
the PiNull Bredevoort mutation is missing (Figure 2b).
Control sequences show only the normal C-allele at both
DNA and cDNA level (Figure 2c and d). Sequence analysis of
exon 2 from father and brother of the proband confirmed
the presence of a heterozygous PiNull Bredevoort mutation
(Figure 2e and f).
Characteristics of Null/Null, ZZ, and SZ subjects
The demographic characteristics of all subjects, their lung
function values and protein serum levels are shown in
Table 5. The mean age difference between groups was 0.5
years (2.7) and the mean difference in smoking history 0.8
pack-years (4.1). Being the groups matched for age and
smoking history, no significant differences were observed in
these parameters (p40.5 for all comparisons).
Severity of emphysema
The comparisons of lung function measurements are
presented in Figure 3. Significant differences among the
groups were detected for both ppFEV1 (p ¼ 0.000) and
ppKCO (p ¼ 0.001). Post-hoc analysis showed lower values of
ppFEV1 in Null/Null as compared to ZZ (p ¼ 0.002), and to SZ
subjects (p ¼ 0.000). Interestingly, a trend but not a
statistically significant difference in FEV1 was observed
between the ZZ and SZ group (p ¼ 0.062). Similar results
were obtained from the comparison of ppKco in the three
groups, with lower values in Null/Null as compared to ZZ
(p ¼ 0.000) and to SZ (p ¼ 0.007). No significant difference
was observed between ZZ and SZ (p ¼ 0.16).
Correlation with AAT serum levels
Considering ZZ and SZ as a combined group, we found a
positive correlation between severity of emphysema,
represented by ppFEV1 and ppKCO, and serum levels of AAT
(Figure 4). The levels of AAT in the serum of Null/Null
subjects were all so low (o0.25 mM) that, although even in
this group there was a positive correlation between lung
function and levels, the authors doubted whether inter-
subject differences in this group could be considered
biologically relevant.
Discussion
In this study, we showed that subjects with absent serum
AAT due to homozygous Null mutations present more severe
pulmonary emphysema than subjects with ZZ or SZ muta-
tions. This finding, and the correlation between AAT levels
and lung function in SZ and ZZ that were matched for age
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Figure 2 DNA and cDNA sequences of part of exon 5 for the proband of family E (a and b) and a control person (c and d). At DNA
level the proband of family E is heterozygous for the PiM Heerlen mutation (a), while the control is homozygous for the normal
proline (c). At cDNA level the proband only shows expression of the CTC codon (PiM Heerlen) and absence of the CCC allele
(hemizygous sequence, (b)). The control expresses both normal CCC alleles (d). Sequence of exon II of the father (e) and brother (f)
of the proband confirmed the presence of a heterozygous PiNull Bredevoort mutation at DNA level.
Alpha-1 antitrypsin Null mutations and severity of emphysema 881and smoking history, suggest that the severity of emphysema
in AATD is strongly determined by the serum levels of the
protein. Furthermore, we characterized and genotyped the
largest population of Null/Null subjects ever described, and
found a new Null mutation at position 548 in exon 2 of
SERPINA1 (Pi Null Bredevoort).
Until now only a very limited number of Null/Null subjects
had been studied and even though they appeared to have
worse lung function than other phenotypes, the limited
number of cases and the confounding by smoking did not
allow drawing a clear conclusion.15,25 The population of our
study is larger, matched for age and smoking history with ZZ
and SZ, and all lung function values were obtained post-
bronchodilator.19,20 Thus, on the basis of our results we
conclude that subjects carrying Null homozygous mutations
should be considered a subgroup at particularly high risk of
emphysema within AATD. It is important to raise more
awareness about this rare but very severe condition within
the medical community, for early detection of carriers of
this genotype. Furthermore, an important implication of our
study is that Null/Null subjects could possibly benefit from
early prophylactic treatment with replacement therapy.
The correlation between severity of the disease and AAT
serum levels is an interesting matter for discussion. A widerange of AAT concentrations and lung function values are
represented in our ZZ and SZ populations, thus a positive
correlation between AAT serum levels and lung function
values contains important information. Even though the
association between variants characterized by very low
levels of AAT (ZZ, rare variants, and Null/Null) and
emphysema severity has been reported in several publica-
tions since the discovery of AATD (reviewed in Ref. 1), a
direct correlation between lung function and protein serum
levels has, to the knowledge of the authors, never been
reported. Possible reasons include lack of adequate number
of cases (Null and rare variants), possible other mechanisms
of lung damage (ZZ mutations), confounding by smoking,
and lack of adequately standardized lung function measure-
ments. Furthermore, ascertainment bias could have led to
overestimate the risk in referred ZZ populations,26 and AAT
replacement therapy gave controversial results on lung
function outcomes in clinical trials, thereby not always
supporting a direct relationship between AATconcentrations
and severity/progression of emphysema.27–30 The possibility
of smoking as a confounder in our study is run out by the
matching criteria. Ascertainment is always a critical point in
studies concerning rare diseases.26 For most rare diseases,
including AATD, neonatal screening is not recommended;
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L. Fregonese et al.882therefore the subjects known to have the genetic defect are
referred because they present the disease or because of
family screening. In a recently published review of the
methodology of the AIR Registry, ascertainment was due to
lung/liver disease in 68.8% and to family screening in 19.2%
of the subjects, similarly to what described in the National
Heart, Lung and Blood Institute registry (72.3 and 19.8,
respectively).17 The Null subjects of our study were
ascertained because of lung disease in 75% of cases and
for family screening in the remaining 25%. Similar percen-
tages were found for ascertainment reasons in the ZZ and SZ
subjects of our study. Therefore, we consider our study
population representative of the general, known, AATD
population.
In ZZ subjects, the presence of polymerized AAT in the
lungs is thought to contribute to the pathogenesis of
emphysema and may account for the difference in lung
disease reported in the literature between ZZ and SZ
patients.1,31 Polymers of AAT are chemotactic to neutrophils
in vitro and co-localize with neutrophils in the alveoli, where
they can work as a proinflammatory stimulus, exacerbating
the lung disease of ZZ subjects.32,33 The magnitude of this
effect can now be put into perspective against what is seen in
our Null/Null subjects. There is no polymer formation in
these individuals, yet the lung function of this population is
significantly worse than that of ZZ, suggesting that low serum
levels of AAT could be more important in the development of
emphysema than the combination of low serum level and
Z-AAT polymer formation.
We described a new mutation in the coding regions of
SERPINA1 in two different families. This new mutation,
called PiNull Bredevoort, is a nucleotide substitution
mutation causing a premature stop codon in exon 2 and
was identified in homozygous state in two sibs, and in
heterozygous state in three members of another family. The
Bredevoort mutation occurs at the same position as the
Granite Falls mutation. In the Pi Null Granite Falls, deletion
of a C-nucleotide causes a frameshift and a direct
premature stop codon in the same position (Y160X) where
a G-nucleotide substitutes a C-nucleotide in the PiNull
Bredevoort mutation. Studies into the intra-cellular me-
chanism using Northern blot analysis showed no detectable
levels of AAT mRNA in alveolar macrophages of homozygous
PiNull Granite Falls mutation.34 Thus, the same mechanism
is probably involved in causing total absence of serum
protein in the PiNull Bredevoort mutation.35,36
A possible limitation of our study is the small size of the
study population. AATD is a rare disease, according to the
definition of rare diseases as those with a prevalence equal
or lower than 1 in 2000. The Null variants, which exact
prevalence is not known, represent an extremely rare
condition within AATD. Indeed, only three other Null/Null
subjects have been registered in the whole AIR database
besides the subjects of our study. For these reasons, our
study population can be considered as representative of the
general Null/Null populations.
In conclusion, our study showed that serum levels of AAT
are correlated with the severity of emphysema. Subjects
with Null mutations should be considered a subgroup at
particularly high risk of emphysema within AATD. Early
detection of carriers of this genotype would be important
for preventive and therapeutic interventions.
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Figure 4 Correlation between serum AAT levels and KCO (a) and correlation between AAT serum levels and FEV1 (b) in SZ (triangles)
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Figure 3 Differences in KCO (a) and FEV1 (b) between Null/Null, ZZ, and SZ subjects.
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